In their recent Sports Business Journal article, Knobbe Martens lawyers Jonathan Hyman, Jonathan Menkes, and Edward Nester examine a growing IP challenge in the sports industry: what happens when an…
One Battle After Another: Broad Institute Wins at PTAB in CRISPR Dispute Eric Furman, Ph.D. & Alistair J. McIntyre Interference proceedings, though increasingly rare, are heavily evidence-based and determine which…
Space Force Awards Kratos $447 Million Contract for Missile Warning Tracking Lizzy T. Do & Scott Cromar Kratos wins $447 million contract with U.S. Space Force to develop a ground…
No Do-Overs: Voluntary Dismissal Does Not Reset Deadline for Stay Jeremiah S. Helm, Ph.D. A respondent in an ITC proceeding may not seek a mandatory stay of their refiled declaratory…
In a recent Reuters Westlaw article, Knobbe Martens lawyers Yi Zhou and Ben Katzenellenbogen discuss the Federal Circuit’s decision in USAA v. PNC Bank and its implications for patent eligibility…
Following April 29 oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the closely watched Supreme Court case on whether a generic drug manufacturer can be held liable…
In the latest installment of their monthly Law360 column covering recent noteworthy Federal Circuit decisions, Knobbe Martens partners Sean Murray and Jeremiah Helm discussed the court’s opinion on retroactivity in…
IRVINE, Calif., May 1, 2026 – Knobbe Martens is proud to share the firm received the “Life Sciences Prosecution Firm of the Year” award at the 2026 Life Sciences Patent…
Key Takeaway: The U.S. Patent and Trademark Office’s April 30, 2026 memorandum encourages patent applicants to submit separate declarations supporting “subject matter eligibility” (SMEDs) in response to § 101 rejections….
In a recent article published in the Association of Business Trial Lawyers Report, Knobbe Martens intellectual property lawyers Jared Bunker, Marko Zoretic, and Oren Rosenberg provide an in-depth analysis of…
